Skip to main content

Table 2 Summary of findings table

From: Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis

#

First author

Year

Pilot

ITT sample

PP sample

PP sample > median(43.5)

Attrition rate(%)

‘Main’outcome identified

Nature of‘main’outcome

End-point

A01

Andrade

1991

N

44

33

N

25.0

Ritchie articular index

Continuous

6 months

A05

Bell

2004

Y

62

53

Y

14.5

Tender point pain on palpation

Continuous

3 months

A06

Bonne

2003

N

44

39

N

11.4

Hamilton Rating Scale for Anxiety (HAM-A)

Continuous

10 weeks

A07

Brien

2011

N

32

23

N

28.1

Proportion of patients meeting ACR 20% improvement criteria (‘ACR20 response’)

Dichotomous

28 weeks

A09

Cavalcanti

2003

N

28

20

N

28.6

Responders: patients with more than 50% reduction in pruritus score

Dichotomous

60 days

A10

Chapman

1999

Y

61

50

Y

18.0

SRH-SLPD functional assessment tool: SRS (symptoms) sub-scale

Continuous

4 months

A11

de Lange de Klerk

1994

N

175

170

Y

2.9

Daily total symptom score

Continuous

1 year

A13

Fisher

2006

Y

38

27

N

28.9

VAS of overall symptom severity

Continuous

13 weeks

A14

Frass

2005

N

70

67

Y

4.3

Patient survival

Dichotomous

180 days

A16

Gaucher

1994

N

80

51

Y

36.3

Degree of dehydration

Continuous

12 h

A18

Jacobs

1993

N

34

33

N

2.9

Number of days until fewer than 3 unformed stools for 2 consecutive days

Continuous

Up to 6 days

A19

Jacobs

1994

N

92

81

Y

12.0

Number of days until fewer than 3 unformed stools for 2 consecutive days

Continuous

Up to 5 days

A20

Jacobs

2001

Y

75

75

Y

0.0

Treatment failure

Dichotomous

5 days (cumulative total)

A21

Jacobs

2000

N

126

116

Y

7.9

Number of days until fewer than 3 unformed stools for 2 consecutive days

Continuous

5 days

A22

Jacobs

2005b

Y

53

33

N

37.7

Hot flash severity score

Continuous

12 months

A23

Jacobs

2005a

Y

43

37

N

14.0

Conners Global Index–Parent (CGI-P)—total

Continuous

17 weeks

A24

Jansen

1992

Y

10

4

N

60.0

Endoscopic appearance (grade)

Continuous

12 months

A25

Kainz

1996

N

67

60

Y

10.4

Responders: patients with at least 50% reduction in area of skin affected by warts

Dichotomous

8 weeks

A26

Katz

2005

Y

7

3

N

57.1

Hamilton Depression Scale (HAMD)

Continuous

12 weeks

A30

Naudé

2010

N

33

30

N

9.1

Sleep Impairment Index (SII) summary score

Continuous

4 weeks

A31

Rastogi ( a)

1999

N

50

42

N

16.0

CD4+ T-lymphocyte counts

Continuous

6 months

A31

Rastogi ( b)

1999

N

50

38

N

24.0

CD4+ T-lymphocyte counts

Continuous

6 months

A32

Sajedi

2008

N

24

16

N

33.3

Modified Ashworth Scale: measurement of muscle tone in right leg

Continuous

4 months

A33

Siebenwirth

2009

N

24

14

N

41.7

MP (multiparameter dermatitis) score

Continuous

32 weeks

A34

Steinsbekk

2005

N

251

199

Y

20.7

Parent-reported URTI total symptom score

Continuous

Duration of 12 weeks

A35

Straumsheim

2000

N

73

68

Y

6.8

Frequency of migraine attacks per month

Continuous

Last month of 4-month period

A36

Thompson

2005

Y

53

45

Y

15.1

MYMOP profile score

Continuous

16 weeks

A37

Walach

1997

N

98

92

Y

6.1

Frequency of headaches per month

Continuous

Last month of 3-month period

A38

Weatherley- Jones

2004

N

103

86

Y

16.5

Responders: those with clinical improvement (Multidimensional Fatigue Inventory: mental fatigue)

Dichotomous

7 months

A39

White

2003

N

89

74

Y

16.9

Childhood Asthma Questionnaire (CAQ) sub-scale for severity of symptoms

Continuous

52 weeks

A40

Whitmarsh

1997

N

63

60

Y

4.8

Frequency of migraine attacks per month

Continuous

Last month of 4-month period

A41

Yakir

2001

Y

23

19

N

17.4

Menstrual distress questionnaire (MDQ) score

Continuous

Duration of 3 months (last 7 days per cycle)

  1. ITT intention to treat, PP per protocol, Y yes, N no.